Pharmacokinetics and interactions of raltegravir;Farmacocinética e interacciones del raltegravir

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 12, 2008, Pages 23-28

  Alsina, Maria Mercè Placeres ^a   Tuset Creus, Montse ^a   Miró, José M ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiretroviral drugs; Cytochrome P450; Integrase inhibitors; Interactions; Pharmacokinetics; Raltegravir

Indexed keywords

ATAZANAVIR; CYTOCHROME P450; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; MIDAZOLAM; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE; INTEGRASE INHIBITOR;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; NONHUMAN; REVIEW; VIRUS REPLICATION; ADULT; AGED; CHILD; DIET RESTRICTION; DRUG DETOXIFICATION; DRUG INTERACTION; ENZYMOLOGY; FEMALE; FOOD DRUG INTERACTION; GENETICS; INTESTINE ABSORPTION; LIVER MICROSOME; MALE; METABOLISM; POLYPHARMACY; PREGNANCY; PREGNANCY COMPLICATION;

ADULT; AGED; ANTI-HIV AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; MALE; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; POLYPHARMACY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRROLIDINONES;

EID: 75149147325     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76569-8     Document Type: Article

References (24)

1. Merck & Co Inc. Isentress® Prescribing Information. Diciembre 2007 [citado 28 Ene 2008]. Agencia Europea del Medicamento (EMEA). Disponible en: http://emea.europa.eu/humandocs/PDFs/EPAR/isentress/H-860-PI-es.pdf
2. M.D. Miller, W. Witmer, K. Stillmock, P. Felock, L. Ecto, J. Flynn, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase inhibitor 16th International AIDS Conference Toronto, Canada. August 13-18 2006 Abstract THAA0302
3. L. Wenning, M. Anderson, A. Petry, E. Friedman, J. Kost, S. James, et al. Raltegravir dose proportionality and effect of food 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL. September 17-20 2007 Abstract H-1046
4. M. Iwamoto, L.A. Wenning, A.S. Petry, M. Laethem, M. De Smet, J.T. Kost, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects Clin Pharmacol Ther 83 2008 293 299
5. A. Petry, L.A. Wenning, T. Laethem, M. De Smet, J.T. Kost, S. Merschman, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of MK-0518 in healthy subjects 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA. September 27-30 2006 Abstract A-376
6. M. Markowitz, J.O. Morales-Ramírez, B.Y. Nguyen, C.M. Kovacs, R.T. Steigbigel, and D.A. Cooper Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals J Acquir Immune Defic Syndr 43 2006 509 515 (Pubitemid 44885615)
7. K. Kassahun, I. McIntosh, D. Cui, D. Hreniuk, M. Merschman, and K. Lasseter Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme Drug Metab Dispos 35 2007 1657 1663 (Pubitemid 47296061)
8. Clinical Trials. Safety and effectiveness of raltegravir (MK-0518) in treatment-experienced, HIV infected children and adolescents [citado 17 Dic 2007]. Disponible en: http://clinicaltrials.gov/show/NCT00485264
9. A.S. Petry, W.D. Hanley, G. Silk, J.T. Kost, S.A. Merschman, R. Robson, et al. Effect of severe renal insufficiency on raltegravir pharmacokinetics 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL. September 17-20 2007 Abstract A-1424
10. A. Telenti, and U.M. Zanger Pharmacogenetics of anti-HIV drugs Annu Rev Pharmacol Toxicol 48 2008 9.1 9.30 30
11. M. Iwamoto, K. Kassahun, M.D. Troyer, W.D. Hanley, P. Lu, A. Rhoton, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation J Clin Pharmacol 48 2008 209 214
12. L.A. Wenning, E. Friedman, J.T. Kost, S. Merschman, K. Lasseter, N. Azrolan, et al. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF) 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA. September 27-30 2006 Abstract A-375
13. M. Markowitz, B.Y. Nguyen, E. Gotuzzo, F. Mendo, W. Ratanasuwan, and C. Kovacs Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naïve patients with HIV-1 infection. Results of a 48-week controlled study J Acquir Immune Defic Syndr 46 2007 125 133 (Pubitemid 47482607)
14. M. Iwamoto, L.A. Wenning, A.S. Petry, T. Laethem, M. Desmet, J.T. Kost, et al. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of MK-0518 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA. September 27-30 2006 Abstract A-373
15. M.S. Anderson, T.N. Kakuda, J.L. Miller, M. Simonts, D. Miller, W. Hanley, et al. Pharmacokinetic evaluation of non-nucleoside reverse transcriptase inhibitor and integrase inhibitor raltegravir in healthy subjects 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention Sydney, Australia. July 22-25 2007 Abstract TUPDB02
16. K. Long, C. Soulié, L. Schneider, J. Ghosn, C. Piketty, F. Boué, et al. Monitoring of raltegravir (MK-0518) in experienced HIV patients 11th European AIDS Conference Madrid, Spain. October 22-24 2007 Abstract PS4/6
17. G.C. Mistry, L.A. Wenning, S. Merschman, J.T. Kost, W.E. Bridson, J.A. Stone, et al. Atazanavir and ritonavir increase plasma levels of MK-0518 8th International Congress on Drug Therapy in HIV Infection Glasgow, UK. November 12-16 2006 Abstract P291
18. B. Grinsztejn, B.Y. Nguyen, C. Katlama, J.M. Gatell, A. Lazzarin, and D. Vittecoq Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial Lancet 369 2007 1261 1269 (Pubitemid 46553846)
19. Tuset M, Miró JM, Codina C, Ribas J. Guía de interacciones farmacológicas en VIH [citado 13 Dic 2007]. Disponible en: http://www.interaccioneshiv.com
20. L.A. Wenning, H. Hanley, J. Stone, A. Moreau, J.T. Kost, E. Mangin, et al. Effect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK-0518 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA. September 27-30 2006 Abstract A-374
21. P. Kumar, D. Cooper, R. Steigbigel, J. Zhao, H. Teppler, and B.Y. Nguyen Efficacy of raltegravir, an HIV integrase inhibitor, in combination with regimens containing enfuvirtide, darunavir, or tipranavir in patients with triple-class resistant virus: combined results from Benchmrk-1 and Benchmrk-2 European AIDS Conference Madrid. October 24-27 2007 Abstract P7
22. M. Iwamoto, L.A. Wenning, S.Y. Liou, J.T. Kost, E. Mangin, K.M. Strohmaier, et al. Rifampin modestly reduces plasma levels of MK-0518 8th International Congress on Drug Therapy in HIV Infection Glasgow, UK. November 12-16 2006 Abstract P299
23. M. Abate, S. Beaird, and J. Siepler Drugdex® Editorial Staff Drug evaluation monographs. Drugdex® Information System 2007 Micromedex Denver, Colorado
24. M.S. Anderson, L.A. Wenning, A. Moreau, J.T. Kost, F.A. Bieberdorf, J.A. Stone, et al. Effect of raltegravir on the pharmacokinetics of oral contraceptives 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL. September 17-20 2007 Abstract A-1425